http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 02 Oct 2026 16:20:38 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/NeuroSense+faces+Nasdaq+delisting+risk+over+market+value+rule/27142566.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced it received a Staff Determination from Nasdaq's Listing Qualifications Department on October 1, 2026, stating the company has not regained compliance with Nasdaq Listing Rule 5550(b)(2), which requires a minimum market value of listed securities (MVLS) of $35 million for continued listing on The Nasdaq Capital Market.</p><p>The company was first notified on April 2, 2026, that its MVLS had fallen below $35 million for 30 consecutive trading days. Under Nasdaq rules, NeuroSense was given 180 calendar days, until September 29, 2026, to regain compliance. Having failed to meet that deadline, Nasdaq determined that the http://www.streetinsider.com/Corporate+News/NeuroSense+faces+Nasdaq+delisting+risk+over+market+value+rule/27142566.html Fri, 02 Oct 2026 16:20:38 -0400 NRSN NRSNW http://www.streetinsider.com/Hot+Corp.+News/NeuroSense+faces+Nasdaq+delisting+risk+over+market+value+rule/27142566.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced it received a Staff Determination from Nasdaq's Listing Qualifications Department on October 1, 2026, stating the company has not regained compliance with Nasdaq Listing Rule 5550(b)(2), which requires a minimum market value of listed securities (MVLS) of $35 million for continued listing on The Nasdaq Capital Market.</p><p>The company was first notified on April 2, 2026, that its MVLS had fallen below $35 million for 30 consecutive trading days. Under Nasdaq rules, NeuroSense was given 180 calendar days, until September 29, 2026, to regain compliance. Having failed to meet that deadline, Nasdaq determined that the http://www.streetinsider.com/Hot+Corp.+News/NeuroSense+faces+Nasdaq+delisting+risk+over+market+value+rule/27142566.html Fri, 02 Oct 2026 16:20:38 -0400 NRSN NRSNW http://www.streetinsider.com/Corporate+News/NeuroSense+faces+Nasdaq+delisting+risk+over+market+value+rule/27142566.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced it received a Staff Determination from Nasdaq's Listing Qualifications Department on October 1, 2026, stating the company has not regained compliance with Nasdaq Listing Rule 5550(b)(2), which requires a minimum market value of listed securities (MVLS) of $35 million for continued listing on The Nasdaq Capital Market.</p><p>The company was first notified on April 2, 2026, that its MVLS had fallen below $35 million for 30 consecutive trading days. Under Nasdaq rules, NeuroSense was given 180 calendar days, until September 29, 2026, to regain compliance. Having failed to meet that deadline, Nasdaq determined that the http://www.streetinsider.com/Corporate+News/NeuroSense+faces+Nasdaq+delisting+risk+over+market+value+rule/27142566.html Fri, 02 Oct 2026 16:20:38 -0400 NRSN NRSNW http://www.streetinsider.com/Hot+Corp.+News/NeuroSense+faces+Nasdaq+delisting+risk+over+market+value+rule/27142566.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced it received a Staff Determination from Nasdaq's Listing Qualifications Department on October 1, 2026, stating the company has not regained compliance with Nasdaq Listing Rule 5550(b)(2), which requires a minimum market value of listed securities (MVLS) of $35 million for continued listing on The Nasdaq Capital Market.</p><p>The company was first notified on April 2, 2026, that its MVLS had fallen below $35 million for 30 consecutive trading days. Under Nasdaq rules, NeuroSense was given 180 calendar days, until September 29, 2026, to regain compliance. Having failed to meet that deadline, Nasdaq determined that the http://www.streetinsider.com/Hot+Corp.+News/NeuroSense+faces+Nasdaq+delisting+risk+over+market+value+rule/27142566.html Fri, 02 Oct 2026 16:20:38 -0400 NRSN NRSNW http://www.streetinsider.com/Press+Releases/NeuroSense+Provides+Update+on+Nasdaq+Listing+Compliance/27142395.html <div class="xn-content"> <p class="prntac">Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a <span>Nasdaq Hearings Panel</span> hearing to seek additional time to regain compliance with the minimum market value requirement</p> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Oct. 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing http://www.streetinsider.com/Press+Releases/NeuroSense+Provides+Update+on+Nasdaq+Listing+Compliance/27142395.html Fri, 02 Oct 2026 16:15:00 -0400 NRSN NRSNW http://www.streetinsider.com/PRNewswire/NeuroSense+Provides+Update+on+Nasdaq+Listing+Compliance/27142395.html <div class="xn-content"> <p class="prntac">Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a <span>Nasdaq Hearings Panel</span> hearing to seek additional time to regain compliance with the minimum market value requirement</p> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Oct. 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing http://www.streetinsider.com/PRNewswire/NeuroSense+Provides+Update+on+Nasdaq+Listing+Compliance/27142395.html Fri, 02 Oct 2026 16:15:00 -0400 NRSN NRSNW http://www.streetinsider.com/Press+Releases/NeuroSense+Provides+Update+on+Nasdaq+Listing+Compliance/27142395.html <div class="xn-content"> <p class="prntac">Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a <span>Nasdaq Hearings Panel</span> hearing to seek additional time to regain compliance with the minimum market value requirement</p> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Oct. 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing http://www.streetinsider.com/Press+Releases/NeuroSense+Provides+Update+on+Nasdaq+Listing+Compliance/27142395.html Fri, 02 Oct 2026 16:15:00 -0400 NRSN NRSNW http://www.streetinsider.com/PRNewswire/NeuroSense+Provides+Update+on+Nasdaq+Listing+Compliance/27142395.html <div class="xn-content"> <p class="prntac">Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a <span>Nasdaq Hearings Panel</span> hearing to seek additional time to regain compliance with the minimum market value requirement</p> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Oct. 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing http://www.streetinsider.com/PRNewswire/NeuroSense+Provides+Update+on+Nasdaq+Listing+Compliance/27142395.html Fri, 02 Oct 2026 16:15:00 -0400 NRSN NRSNW http://www.streetinsider.com/Press+Releases/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html <div class="xn-content"> <p><i>The planned submission follows alignment with <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> (the "Agency") for PrimeC for the treatment of amyotrophic http://www.streetinsider.com/Press+Releases/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html Wed, 22 Jul 2026 08:30:00 -0400 A.06822034 A.17150087 NRSN NRSNW O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/PRNewswire/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html <div class="xn-content"> <p><i>The planned submission follows alignment with <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> (the "Agency") for PrimeC for the treatment of amyotrophic http://www.streetinsider.com/PRNewswire/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html Wed, 22 Jul 2026 08:30:00 -0400 A.06822034 A.17150087 NRSN NRSNW O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Press+Releases/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html <div class="xn-content"> <p><i>The planned submission follows alignment with <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> (the "Agency") for PrimeC for the treatment of amyotrophic http://www.streetinsider.com/Press+Releases/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html Wed, 22 Jul 2026 08:30:00 -0400 A.06822034 A.17150087 NRSN NRSNW O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/PRNewswire/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html <div class="xn-content"> <p><i>The planned submission follows alignment with <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> (the "Agency") for PrimeC for the treatment of amyotrophic http://www.streetinsider.com/PRNewswire/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html Wed, 22 Jul 2026 08:30:00 -0400 A.06822034 A.17150087 NRSN NRSNW O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Press+Releases/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html <div class="xn-content"> <p><i>The planned submission follows alignment with <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> (the "Agency") for PrimeC for the treatment of amyotrophic http://www.streetinsider.com/Press+Releases/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html Wed, 22 Jul 2026 08:30:00 -0400 A.06822034 A.17150087 NRSN NRSNW O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/PRNewswire/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html <div class="xn-content"> <p><i>The planned submission follows alignment with <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> (the "Agency") for PrimeC for the treatment of amyotrophic http://www.streetinsider.com/PRNewswire/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html Wed, 22 Jul 2026 08:30:00 -0400 A.06822034 A.17150087 NRSN NRSNW O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Press+Releases/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html <div class="xn-content"> <p><i>The planned submission follows alignment with <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> (the "Agency") for PrimeC for the treatment of amyotrophic http://www.streetinsider.com/Press+Releases/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html Wed, 22 Jul 2026 08:30:00 -0400 A.06822034 A.17150087 NRSN NRSNW O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/PRNewswire/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html <div class="xn-content"> <p><i>The planned submission follows alignment with <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> (the "Agency") for PrimeC for the treatment of amyotrophic http://www.streetinsider.com/PRNewswire/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html Wed, 22 Jul 2026 08:30:00 -0400 A.06822034 A.17150087 NRSN NRSNW O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Press+Releases/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html <div class="xn-content"> <p><i>The planned submission follows alignment with <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> (the "Agency") for PrimeC for the treatment of amyotrophic http://www.streetinsider.com/Press+Releases/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html Wed, 22 Jul 2026 08:30:00 -0400 A.06822034 A.17150087 NRSN NRSNW O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/PRNewswire/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html <div class="xn-content"> <p><i>The planned submission follows alignment with <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> (the "Agency") for PrimeC for the treatment of amyotrophic http://www.streetinsider.com/PRNewswire/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html Wed, 22 Jul 2026 08:30:00 -0400 A.06822034 A.17150087 NRSN NRSNW O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Press+Releases/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html <div class="xn-content"> <p><i>The planned submission follows alignment with <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> (the "Agency") for PrimeC for the treatment of amyotrophic http://www.streetinsider.com/Press+Releases/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html Wed, 22 Jul 2026 08:30:00 -0400 A.06822034 A.17150087 NRSN NRSNW O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/PRNewswire/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html <div class="xn-content"> <p><i>The planned submission follows alignment with <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> (the "Agency") for PrimeC for the treatment of amyotrophic http://www.streetinsider.com/PRNewswire/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html Wed, 22 Jul 2026 08:30:00 -0400 A.06822034 A.17150087 NRSN NRSNW O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Press+Releases/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html <div class="xn-content"> <p><i>The planned submission follows alignment with <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> (the "Agency") for PrimeC for the treatment of amyotrophic http://www.streetinsider.com/Press+Releases/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html Wed, 22 Jul 2026 08:30:00 -0400 A.06822034 A.17150087 NRSN NRSNW O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/PRNewswire/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html <div class="xn-content"> <p><i>The planned submission follows alignment with <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span> (the "Agency") for PrimeC for the treatment of amyotrophic http://www.streetinsider.com/PRNewswire/NeuroSense+Advances+PrimeC+Toward+New+Drug+Submission+to+Health+Canada+for+ALS/26798779.html Wed, 22 Jul 2026 08:30:00 -0400 A.06822034 A.17150087 NRSN NRSNW O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Press+Releases/NeuroSense+to+Participate+in+Roth-Hosted+KOL+Webinar+on+the+Future+of+ALS+Treatment%3A+%26quot%3BA+Quest+to+Outrun+ALS%26quot%3B/26733320.html <div class="xn-content"> <p><i>Featuring renowned ALS expert Prof. <person>Jeremy Shefner</person>, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced its participation in a key opinion leader (KOL) webinar hosted by <span value="ACORN:0185760083" idsrc="xmltag.org" >Roth Capital Partners</span> titled "A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS)." The webinar will bring together leading experts to discuss the current treatment landscape http://www.streetinsider.com/Press+Releases/NeuroSense+to+Participate+in+Roth-Hosted+KOL+Webinar+on+the+Future+of+ALS+Treatment%3A+%26quot%3BA+Quest+to+Outrun+ALS%26quot%3B/26733320.html Mon, 06 Jul 2026 08:45:00 -0400 A.01857600 A.06822034 H1Z NRSN NRSNW O.00080482 O.20026344 O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+to+Participate+in+Roth-Hosted+KOL+Webinar+on+the+Future+of+ALS+Treatment%3A+%26quot%3BA+Quest+to+Outrun+ALS%26quot%3B/26733320.html <div class="xn-content"> <p><i>Featuring renowned ALS expert Prof. <person>Jeremy Shefner</person>, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced its participation in a key opinion leader (KOL) webinar hosted by <span value="ACORN:0185760083" idsrc="xmltag.org" >Roth Capital Partners</span> titled "A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS)." The webinar will bring together leading experts to discuss the current treatment landscape http://www.streetinsider.com/PRNewswire/NeuroSense+to+Participate+in+Roth-Hosted+KOL+Webinar+on+the+Future+of+ALS+Treatment%3A+%26quot%3BA+Quest+to+Outrun+ALS%26quot%3B/26733320.html Mon, 06 Jul 2026 08:45:00 -0400 A.01857600 A.06822034 H1Z NRSN NRSNW O.00080482 O.20026344 O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+to+Participate+in+Roth-Hosted+KOL+Webinar+on+the+Future+of+ALS+Treatment%3A+%26quot%3BA+Quest+to+Outrun+ALS%26quot%3B/26733320.html <div class="xn-content"> <p><i>Featuring renowned ALS expert Prof. <person>Jeremy Shefner</person>, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 6, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced its participation in a key opinion leader (KOL) webinar hosted by <span value="ACORN:0185760083" idsrc="xmltag.org" >Roth Capital Partners</span> titled "A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS)." The webinar will bring together leading experts to discuss the current treatment landscape http://www.streetinsider.com/Press+Releases/NeuroSense+to+Participate+in+Roth-Hosted+KOL+Webinar+on+the+Future+of+ALS+Treatment%3A+%26quot%3BA+Quest+to+Outrun+ALS%26quot%3B/26733320.html Mon, 06 Jul 2026 08:45:00 -0400 A.01857600 A.06822034 H1Z NRSN NRSNW O.00080482 O.20026344 O.31364977